IP Library › Granted Patent US 10,941,208
Granted Patent B2
US 10,941,208 · App. 15/713,578 · Granted Mar 9, 2021

Anti-MUC16 antibodies

Inventors: Lauric Haber (Rye Brook, NY); Eric Smith (New York, NY); Marcus Kelly (New York, NY); Jessica R. Kirshner (New York, NY); Sandra Coetzee (White Plains, NY); Alison Crawford (Dobbs Ferry, NY); Thomas Nittoli (Pearl River, NY); Yashu Liu (Tarrytown, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/3092A61K39/395A61K39/39558A61K47/6849A61K47/6851A61K47/6869C07K16/2809C07K16/2863C07K16/3069C07K16/44C07K16/468G01N33/57492A61K2039/505C07K2317/24C07K2317/31C07K2317/33C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/73C07K2317/92C07K2317/94G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,941,208
App. No.
15/713,578
Granted
Mar 9, 2021
Kind
B2
Abstract

Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Claims (2)

1. An isolated monoclonal antibody or antigen-binding fragment thereof that binds MUC16, wherein the antibody and antigen-binding fragment thereof comprise HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 domains comprising the amino acid sequences of SEQ ID NO: 1946, SEQ ID NO: 1948, SEQ ID NO: 1950, SEQ ID NO: 1954, SEQ ID NO: 1956, and SEQ ID NO: 1958, respectively within an antibody framework, and wherein the HCDR1, HCDR2 and HCDR3 domains are ordered as found in a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1944, and the LCDR1, LCDR2 and LCDR3 domains are ordered as found in a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1952.

2. The antibody or antigen-binding fragment of claim 1 , wherein the antibody and antigen-binding fragment comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1944, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1952.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2018
From: HABER, LAURIC; SMITH, ERIC; KELLY, MARCUS; KIRSHNER, JESSICA R.; COETZEE, SANDRA; CRAWFORD, ALISON; NITTOLI, THOMAS; LIU, YASHU
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 045132/0848 →
Continuity (3)
Provisional Application 62399249 · Sep 23, 2016
Provisional Application 62558711 · Sep 14, 2017
Related Publication 20180118848A1 · May 3, 2018
Cited By (3)
US 12,509,516 US 12,570,764 US 12,577,304